Clinical trial
Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small…
NCT00168922 · Charite University, Berlin, Germany, Other · Unknown status
Key facts
| NCT number | NCT00168922 |
|---|---|
| Title | Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC) |
| Official title | Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Collaborators | ribosepharm GmbH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Bendamustin/Ribomustin |
| Enrollment | 50 |
| Start date | Feb 1, 2001 |
| Completion | Dec 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Apr 27, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: